Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirion Postoperative Ocular Inflammation Candidate Durezol Shows Efficacy In Twice-Daily Dosing In Phase III Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Topical steroid has June 26 FDA action date.

You may also be interested in...



Sirion’s Durezol Cleared For Post-Op Ocular Use

The first-in-class topical steroid is set to launch in the fourth quarter.

Sirion’s Durezol Cleared For Post-Op Ocular Use

The first-in-class topical steroid is set to launch in the fourth quarter.

FDA Panel Mulls Approval Of Sirion’s Durezol

Advisory committee will consider topical ophthalmic steroid for postoperative ocular inflammation and pain on May 29.

Related Content

Topics

UsernamePublicRestriction

Register

PS067714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel